RFS and OS from CR according to the new risk classification. RFS and OS from CR are shown for patients also investigated for relevant oncogenetic events (MLL gene rearrangement and IKZF1 gene deletion in BCP-ALL; NOTCH1/FBXW7/RAS/PTEN anomalies in T-ALL) according to the new risk classification. High-risk patients are defined here as those with high-risk oncogenetics and/or MRD1 response ≥10⁻⁴: (A) RFS in BCP-ALL patients (77 vs 44% at 5 years; HR, 2.84 [95% CI, 1.72-4.70]; P ≤ .001); (B) OS from CR in BCP-ALL patients (79 vs 50% at 5 years; HR, 2.78 [95% CI, 1.61-4.80]; P < .001); (C) RFS in T-ALL patients (86 vs 52% at 5 years; HR, 4.20 [95% CI, 1.85-9.51]; P = .001); (D) OS from CR in T-ALL patients (91 vs 62% at 5 years; HR, 4.14 [95% CI, 1.58-10.83]; P = .004).